Evidence map›Paper›PMID 35028131›Full record

ArticleClinical kidney journal2022

Plasma exchange with COVID-19 convalescent plasma in a patient with severe ANCA-associated vasculitis and COVID-19 pneumonia after rituximab therapy.

Matthias Kochanek, Jorge Garcia Borrega, Laura Beckmann, Julia Neuhann, Birgit S Gathof, Veronica Di Cristanziano, Henning Hagmann, Garcia Borrega

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Matthias KochanekDepartment of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf (CIO ABCD), University of Cologne, Cologne, Germany.
Jorge Garcia BorregaDepartment of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf (CIO ABCD), University of Cologne, Cologne, Germany.
Laura BeckmannDepartment of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf (CIO ABCD), University of Cologne, Cologne, Germany.
Julia NeuhannFaculty of Medicine and University Hospital Cologne, Transfusion Medicine (CIO), University Hospital of Cologne, Cologne, Germany.
Birgit S GathofFaculty of Medicine and University Hospital Cologne, Transfusion Medicine (CIO), University Hospital of Cologne, Cologne, Germany.
Veronica Di CristanzianoFaculty of Medicine and University Hospital Cologne, Institute of Virology, Cologne, Germany.
Henning HagmannDepartment II of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne Cluster of Excellence on Cellular Stress Responses in Ageing-Associated Diseases, Center for Molecular Medicine Cologne, Cologne, Germany.
Garcia BorregaFaculty of Medicine and University Hospital Cologne, Transfusion Medicine (CIO), University Hospital of Cologne, Cologne, Germany.
University Hospital Cologne · DECologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DEDüsseldorf University Hospital · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination of coronavirus disease 2019 (COVID-19) pneumonia and pulmonary-renal syndrome due to ANCA-associated vasculitis (AAV) poses diagnostic uncertainty and a therapeutic dilemma. According to current limited knowledge of COVID-19, the application of commonly used drugs in AAV, cyclophosphamide (CYC) and rituximab (RTX), must be weighed carefully in active COVID-19 infection. We report a case of a 52-year-old male patient with concurrent severe COVID-19 pneumonia and acute relapse of pulmonary-renal syndrome due to AAV after recent RTX maintenance dose. The patient presented with severe hypoxaemia, complete B-cell depletion and severe acute respiratory syndrome coronavirus 2 viraemia. He was successfully treated with therapeutic plasma exchange employing COVID-19 convalescent plasma.

Indexed as

ANCA vasculitisintensive careplasma exchangeplasmapheresispneumoniarituximabSARS-CoV-2

Identifiers

PMID35028131
PMCPMC8244539
OpenAlexW3172366813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.